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Abstract
Trophoblast cells are unique because they are one of the few mammalian cell types that do not
express major histocompatibility complex (MHC) class II antigens, either constitutively or after
exposure to IFN-γ.  The absence of MHC class II antigen expression on trophoblast cells has been
postulated to be one of the essential mechanisms by which the semi-allogeneic fetus evades
immune rejection reactions by the maternal immune system.  Consistent with this hypothesis,
trophoblast cells from the placentas of women suffering from chronic inflammation of unknown
etiology and spontaneous recurrent miscarriages have been reported to aberrantly express MHC
class II antigens.  The lack of MHC class II antigen expression on trophoblast cells is due to silencing
of expression of the class II transactivator (CIITA), a transacting factor that is essential for
constitutive and IFN-γ-inducible MHC class II gene transcription.  Transfection of trophoblast cells
with CIITA expression vectors activates both MHC class II and class Ia antigen expression, which
confers on trophoblast cells both the ability to activate helper T cells, and sensitivity to lysis by
cytotoxic T lymphocytes.  Collectively, these studies strongly suggest that stringent silencing of
CIITA (and therefore MHC class II) gene expression in trophoblast cells is critical for the
prevention of immune rejection responses against the fetus by the maternal immune system.   The
focus of this review is to summarize studies examining the novel mechanisms by which CIITA is
silenced in trophoblast cells.  The elucidation of the silencing of CIITA in trophoblast cells may shed
light on how the semi-allogeneic fetus evades immune rejection by the maternal immune system
during pregnancy.
Introduction
The successful maintenance of the semi-allogeneic mam-
malian fetus during pregnancy provides an apparent
immunological paradox. Despite the fact that the fetus
expresses proteins encoded by paternally-inherited genes,
the maternal immune system does not mount an alloge-
neic rejection response against the fetus. However, fetal or
paternal tissues transplanted into the mother at sites other
than the uterus are efficiently rejected, which suggests that
the pregnant uterus is an immunologically privileged site
[1]. Although the precise mechanisms underlying the lack
of a rejection response against the developing fetus
remain incompletely understood, trophoblast cells clearly
play an essential role in the prevention of these deleteri-
ous immune reactions by several mechanisms. These
include the production of multiple soluble and mem-
brane-bound factors that inhibit lymphocytic function,
and the absence on the trophoblast cell surface of major
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histocompatibility complex (MHC) molecules, which are
required for immune recognition and activation. This
review will focus on the novel mechanisms underlying the
silencing of MHC class II molecule expression on tro-
phoblast cells.
Significance of MHC class II antigens and 
regulation of expression
MHC class II antigens are heterodimeric cell surface glyc-
oproteins that are essential for the activation of CD4+
helper T (TH) lymphocytes, and the subsequent initiation
of antibody- and cytotoxic T lymphocyte (CTL)-based
immune responses [2]. Antigenic peptides bound to MHC
class II molecules on the surface of antigen presenting
cells are recognized by T cell receptors (TCR) on antigen-
specific TH cells. The engagement of antigenic peptide:
MHC class II complexes with TCRs on TH cells results in
activation and clonal expansion of these cells, which sub-
sequently synthesize and secrete cytokines that activate
CTLs or induce the production of antibodies by B cells.
Importantly, allelic differences in MHC class I and class II
antigens between donor and recipient are the primary
molecular basis for immunological rejection of trans-
planted organs, for rejection can occur when MHC class I
or class II antigens on the transplanted organ differing
from the recipient are recognized as "non-self" by the
recipient's immune system [2].
Trophoblast cells are one of the few cell types that do not
express MHC class II or class Ia antigens, either constitu-
tively or after exposure to IFN-γ [3-9]. Understanding the
mechanisms by which MHC class II gene expression is
silenced in trophoblast cells is of intense interest because
of the potential role that the lack of expression of these
antigens plays in protection of the fetus from maternal
immune system attack. Inappropriate MHC class II anti-
gen expression on trophoblast cells could lead to maternal
immune responses against the fetus by either stimulation
of allogeneic rejection reactions against trophoblast
expressing paternally-derived MHC class II antigens, or by
direct presentation of fetally-derived peptides to maternal
helper T cells by MHC class II-positive trophoblast cells.
Consistent with these possibilities, human choriocarci-
noma cell lines engineered to express MHC class II anti-
gens were able to stimulate allogeneic T cell responses,
and present antigen to antigen-specific T cells [10,11].
Furthermore, trophoblast cells from the placentas of
women suffering from chronic inflammation of unknown
etiology and spontaneous recurrent miscarriages have
been reported to aberrantly express MHC class II antigens
[12,13]. Collectively, these results suggest that stringent
silencing of MHC class II antigen expression on trophob-
last cells may be critical for the survival of the fetus during
pregnancy. It is possible, however, that under certain con-
ditions MHC class II expression is induced in the trophob-
last layer following mechanical injury as described by
Sims et al. [14], or during infection by specific pathogens.
Interestingly, MHC class II expression is activated in
mouse trophoblast cells treated with the histone deacety-
lase inhibitor trichostatin A (TSA), which is a fungal prod-
uct [15]. Thus, it is intriguing to speculate that the
presence of fungi in the reproductive tract during preg-
nancy may result in activation of aberrant MHC class II
molecule expression on trophoblast cells, which could
potentially lead to the generation of a deleterious anti-
fetal immune response. Surprisingly, despite the long-
standing and widespread belief that aberrant expression
of MHC class II antigens on trophoblast cells would lead
to immune rejection of the fetus, studies that directly test
this hypothesis have not been reported in the literature.
The expression of MHC class II antigens is regulated pri-
marily at the level of transcription, in a developmental
and tissue-specific manner. Constitutive MHC class II
expression is restricted to professional antigen presenting
cells (APC), which include dendritic cells, macrophages,
thymic epithelial cells and mature B cells [16]. MHC class
II gene expression is downregulated as B cells differentiate
into plasma cells [16]. In contrast to APC, fibroblasts and
cells of endothelial and epithelial origin do not express
class II antigens constitutively, but do so following expo-
sure to IFN-γ [16]. Finally, trophoblast cells, sensory neu-
rons and plasma cells do not express MHC class II
antigens, either constitutively or after exposure to IFN-γ
[16].
The developmental and cell-type specific pattern of MHC
class II gene expression is due to differential expression of
a transacting factor termed the class II transactivator
(CIITA), which is considered to be the "master regulator"
of MHC class II gene transcription [17,18]. Expression of
CIITA is constitutive in mature B cells and dendritic cells,
and is activated by IFN-γ in fibroblasts, epithelial and
endothelial cells [19-21]. The downregulation of MHC
class II transcription during differentiation of B cells into
plasma cells results from silencing of CIITA expression
[22]. Furthermore, the inability of trophoblast cells to
transcribe MHC class II genes, even in the presence of IFN-
γ, is due to silencing of CIITA expression [11,23,24].
Transfection of CIITA expression vectors into trophoblast
cells, plasma cells, and IFN-γ-inducible cells results in
constitutive cell surface expression of MHC class II mole-
cules [11,19-24]. Therefore, efforts to understand the cell
type specific expression of MHC class II antigens have
focused on delineating the mechanisms by which CIITA
expression is controlled.
In addition to activating MHC class II genes, CIITA also
plays an ancillary role in activating transcription of MHC
class I genes in some cell types [25,26]. Importantly,Reproductive Biology and Endocrinology 2004, 2:52 http://www.rbej.com/content/2/1/52
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transfection of JEG-3 choriocarcinoma cells with CIITA
expression vectors resulted in the activation of expression
of both MHC class II molecules [11,23,24] and the MHC
class I molecules HLA-B and HLA-C [11]. MHC class II
expression on the JEG-3 cells conferred the ability to acti-
vate antigen-specific T cells [11]. Furthermore, JEG-3 cells
expressing CIITA were sensitive to MHC-restricted lysis by
cytotoxic T lymphocytes [11]. These studies are consistent
with the hypothesis that inappropriate expression of
CIITA in trophoblast cells can lead to deleterious maternal
immune responses against the conceptus.
Regulation of CIITA gene expression in B cells, 
dendritic cells and IFN-γ-inducible cells
The regulation of constitutive and IFN-γ-inducible CIITA
gene expression is controlled predominantly at the level
of transcription by four different promoters in human
(and three in mice) that function in a cell-type specific
manner [27-32]. Constitutive transcription is mediated by
the type I promoter in dendritic cells and macrophages,
and by the type III promoter in B and activated T cells [27-
30]. The cell type specificity of the type II promoter, which
is unique to humans, is currently unclear [27]. IFN-γ-
inducible CIITA transcription is controlled primarily at
the type IV promoter, although the type III promoter is
weakly IFN-γ-responsive in select cell types [27,28,31,32].
Since the activity of CIITA promoters I and III is restricted
to antigen presenting cells such as dendritic cells and B
cells, investigators studying the regulation of CIITA
expression in trophoblasts have concentrated on deter-
mining the mechanisms involved in silencing from the
IFN-γ-responsive type IV promoter (PIV).
IFN-γ-inducible transcription from the CIITA PIV is medi-
ated by the Janus Kinase-1/Signal Transducers and Activa-
tors of Transcription-1 (JAK-1/STAT-1) signaling pathway
[Figure 1, based on [27,28,31-33]]. Following binding of
IFN-γ to its cognate receptor, JAK-1 becomes activated,
and it phosphorylates STAT-1 that is localized in the cyto-
plasm [34]. Phosphorylated STAT-1 subsequently
homodimerizes and translocates to the nucleus, where it
activates transcription of the gene encoding a transcrip-
tion factor termed interferon regulatory factor-1 (IRF-1),
and a host of other genes including CIITA [27,31-34]. The
CIITA PIV contains three conserved elements, including a
GAS element, which binds to activated STAT-1, an E box,
which binds to the ubiquitously expressed transcription
factor USF-1, and an interferon regulatory element (IRE),
which binds to IRF-1 and IRF-2 [27,31,32]. Mutational
analyses demonstrated that the GAS, E box, and IRE are all
required for IFN-γ-inducible CIITA transcription [31,32].
Consistent with these results, IFN-γ-responsive CIITA
(and class II) expression is abrogated in both IRF-1 and
STAT-1 deficient cells [31,33]. Moreover, the initiation
and maintenance of CIITA transcription requires sus-
tained STAT-1 activation and threshold levels of IRF-1
[35]. Interestingly, the transcription factor IRF-2, which is
constitutively expressed and normally acts as an antago-
nist to IRF-1, also appears to play an essential role in IFN-
γ-inducible CIITA transcription [36-38].
Recent studies indicate that chromatin structure also plays
a crucial role in the transcriptional regulation of CIITA.
For instance, IFN-γ-inducible CIITA transcription requires
the recruitment and activity of the chromatin remodeling
complex SWI/SNF to the CIITA type IV promoter [39]. In
addition, studies utilizing chromatin immunoprecipita-
tion assays revealed that acetylation of histones H3 and
H4 occurs at the CIITA PIV following exposure of fibrob-
last and epithelial cells to IFN-γ, and that histone acetyla-
tion is associated with successful IFN-γ-inducible CIITA
transcription [40]. It is currently unclear how histone
acetyltransferases (HATs) are recruited to the CIITA pro-
moter following IFN-γ treatment. One possibility is that
STAT-1 and IRF-1 recruit the HATs CBP, pCAF, and/or 300
to the CIITA promoter, for physical interactions between
STAT-1, IRF-1 and these HATs have been detected at other
IFN-γ-responsive promoters [41]. This is consistent with
studies demonstrating that the increase in histone acetyla-
tion at the CIITA promoter is coincident with binding of
STAT-1 in IFN-γ-treated cells [40]. In summary, studies to
date indicate that successful IFN-γ-inducible CIITA tran-
scription requires: 1) sufficient and sustained levels of
activated STAT-1, IRF-1 and IRF-2, 2) acetylation of his-
tones at the CIITA PIV, and 3) chromatin remodeling by
the SWI/SNF complex.
Regulation of CIITA gene expression in 
trophoblast cells
As mentioned previously, the inability of human, mouse
and rat trophoblast cells to express MHC class II mole-
cules in response to IFN-γ is due to the silencing of CIITA
transcription [11,23,24]. Transient transfection assays
demonstrated that the IFN-γ-responsive CIITA type IV
promoter is functionally active in trophoblast cells,
despite the fact that the endogenous CIITA gene is not
expressed [11,15,42]. These results suggested that tro-
phoblast cells contain the transacting DNA binding fac-
tors (STAT-1, USF-1 and IRF-1) required for IFN-γ-
inducible CIITA transcription. Furthermore, these data are
consistent with a model in which endogenous CIITA tran-
scription in trophoblast cells is repressed by epigenetic
mechanism(s) which maintain a closed chromatin con-
formation, such as promoter methylation and/or the
insufficient acetylation of histones. Epigenetic repression
is also consistent with the following observations: 1) nei-
ther STAT-1 nor IRF-1 are bound to the GAS and IRE of the
CIITA PIV in IFN-γ-treated Jar and JEG-3 choriocarcinoma
cells, and 2) the histones H3 and H4 are not acetylated atReproductive Biology and Endocrinology 2004, 2:52 http://www.rbej.com/content/2/1/52
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the CIITA PIV in these choriocarcinoma cells following
exposure to IFN-γ [40,42].
The CIITA type IV promoter was shown to be methylated
in Jar and JEG-3 cells [11,15,42,43], and in human chori-
onic villous trophoblast cells isolated from first trimester
placentas [11,44]. Moreover, Morris et al. [42] and van der
Stoep et al. [44] reported that Jar and JEG-3 cells treated
sequentially with the demethylating agent 5-azacytidine
followed by IFN-γ expressed low levels of CIITA and MHC
class II mRNA. These collective results led to the hypothe-
sis that methylation of CIITA PIV is responsible for repres-
sion of IFN-γ-inducible CIITA transcription in trophoblast
cells. Contrary to these studies, recent work from our lab-
oratory demonstrated that the CIITA PIV is not methyl-
ated in primary human cytotrophoblast cells freshly
IFN-γ-inducible CIITA transcription from the type IV promoter is mediated by the Janus Kinase-1/Signal Transducers and Acti- vators of Transcription-1 (JAK-1/STAT-1) signaling pathway Figure 1
IFN-γ-inducible CIITA transcription from the type IV promoter is mediated by the Janus Kinase-1/Signal 
Transducers and Activators of Transcription-1 (JAK-1/STAT-1) signaling pathway. Binding of IFN-γ to the IFN-γ 
receptor (IFN-γ-R) results in activation of the kinases JAK-1 and JAK-2. These kinases subsequently phosphorylate the IFN-γ-R, 
which leads to a conformational change in the receptor that provides a docking site for monomers of the transcription factor 
STAT-1 that are localized in the cytoplasm. These STAT-1 monomers are phosphorylated by the JAKs, which leads to dimeri-
zation and translocation to the nucleus. STAT-1 activates transcription of a variety of genes, including the transacting factor 
interferon regulatory factor-1 (IRF-1), by binding to γ-activating sequences (GAS) within the promoters of the target genes. 
Phosphorylated STAT-1, IRF-1, and the ubiquitously expressed factors USF-1 and IRF-2 subsequently cooperate to activate 
CIITA transcription by binding to the GAS, E box and interferon responsive element (IRE), respectively, in the CIITA type IV 
promoter.
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isolated from term placentas, or in mouse or rat trophob-
last cell lines. In addition, CIITA PIV is methylated in
human 2fTGH fibrosarcoma cells, which are IFN-γ-induc-
ible for CIITA expression [15]. Based on the studies by van
den Elsen's group [44] and our group [15], it is possible
that the methylation status of CIITA PIV in human tro-
phoblast cells may vary during different stages of preg-
nancy. However, the collective results from our laboratory
[15] strongly suggest that silencing of IFN-γ-inducible
CIITA transcription in trophoblast cells is not due to
methylation of the CIITA PIV.
CIITA gene expression is activated in mouse trophoblast
cell lines treated with the combination of IFN-γ and the
histone deacetylase (HDAC) inhibitor trichostatin A
(TSA) [15], which indicates that HDACs are involved in
silencing CIITA transcription in these cells. Furthermore,
the demonstration that histones H3 and H4 are not
acetylated at the CIITA PIV in Jar or JEG-3 choriocarci-
noma cells after exposure to IFN-γ [40] suggest that the
appropriate histone acetyltransferases (HATs) are either
insufficiently expressed, and/or not effectively recruited to
the CIITA PIV in trophoblast cells exposed to IFN-γ. Since
acetylation is closely associated with an open chromatin
conformation and successful transcription, these results
support the concept that CIITA transcription is silenced in
trophoblast cells by an epigenetic mechanism that results
in a closed chromatin conformation at CIITA PIV.
As mentioned previously, the CIITA PIV is inducible by
IFN-γ in transient transfection assays of trophoblast cells,
which suggests that these cells contain the transacting fac-
tors (STAT-1, USF-1, IRF-1 and IRF-2) required for IFN-γ-
inducible CIITA transcription. However, recent data from
our laboratory demonstrate that although basal STAT-1
expression is comparable in human trophoblast versus
HeLa cells, the IFN-γ induced levels of the STAT-1, IRF-1,
and IRF-2 transcription factors are significantly reduced in
trophoblast cells relative to HeLa or 2fTGH fibrosarcoma
cells [45]. Similar results were observed in studies of
mouse trophoblast cell lines [46]. These collective results
can be interpreted at least two different ways: 1) trophob-
last cells express sufficient levels of activated STAT-1, IRF-
1 and IRF-2 to drive IFN-γ-inducible transcription from
CIITA PIV; or 2) the chromatin structure may affect the rel-
ative amounts of STAT-1 and IRFs required to activate the
CIITA PIV. In the latter instance, the endogenous PIV may
require higher levels of the transcription factors for activa-
tion than the transfected, unintegrated CIITA PIV. The
reduced levels of STAT-1 and IRF-1 in IFN-γ-treated tro-
phoblast cells may also help account for: 1) why binding
of these factors to the CIITA PIV has not been detected by
in vivo genomic footprinting or chromatin immunopre-
cipitation assays of trophoblast cells [40-42], and 2) the
lack of histone acetylation at the CIITA promoter in these
cells, for both STAT-1 and IRF-1 recruit histone acetyl-
transferases (HATs) to IFN-γ-responsive promoters [41].
Further studies are clearly required to address these issues.
A novel method for actively repressing CIITA transcription
in trophoblast cells was proposed based on studies in
which HeLa cells (which express CIITA in response to IFN-
γ) were transfected with a Jar cell cDNA expression library,
and negatively selected for MHC class II expression [47-
49]. An untranslated poly A+ RNA (utRNA) was identified
in choriocarcinoma cells that could repress CIITA and
MHC class II expression when transfected into either HeLa
cells or CH27 mouse B cells. However, the precise mecha-
nism by which this utRNA may suppress CIITA transcrip-
tion is currently unclear. Peyman [47] reported that this
RNA contains STAT-1 (GAS) binding motifs, and pro-
posed that by competitively binding to activated STAT-1
in the cytoplasm, the utRNA blocks STAT-1 nuclear trans-
location and therefore IFN-γ-inducible gene transcription.
In contrast, Geirsson et al. [48] stated that this utRNA
blocked CIITA type IV promoter activity in transient trans-
fection assays of HeLa cells, and that the sequences of the
CIITA PIV between the GAS and IRE were required for
transcriptional repression. These results appear to contrast
with the work of three other groups [11,15,42] showing
that the CIITA PIV is active in transient transfection assays
of trophoblast cells. In a separate study, Geirsson et al.
[49] also showed that this trophoblast utRNA inhibited
transcription from the B cell-specific CIITA type III pro-
moter when transfected into CH27 murine B cells. The
CIITA type III promoter fragment utilized in these studies
does not contain a GAS, and the specific CIITA PIII
sequences required for transcriptional repression were not
identified in this study. Thus, further studies are necessary
to elucidate the precise role that this utRNA may play in
silencing CIITA transcription in trophoblast cells.
As an additional means to investigate the genetic mecha-
nisms regulating CIITA and MHC class II gene expression
in trophoblast, stable heterokaryons were generated
between trophoblast and CIITA-expressing cells [15,50].
Neither CIITA nor MHC class II molecules were expressed
in stable hybrids between Jar cells and B cells, suggesting
that silencing of transcription from the B cell-specific
CIITA PIII is dominant in trophoblast cells [50]. In con-
trast, hybrids between human Jar or JEG-3 cells and
2fTGH fibrosarcoma cells expressed both CIITA and MHC
class II following exposure to IFN-γ [15], indicating that
silencing of IFN-γ-inducible transcription from the CIITA
PIV in trophoblast cells is recessive. Identical results were
obtained in studies of hybrids between mouse M-11 tro-
phoblast cells and NIH-3T3 fibroblasts [15]. One explana-
tion for the recessive nature of the silencing of IFN-γ-
inducible CIITA transcription is that trophoblast cells
express insufficient levels of essential transacting factor(s),Reproductive Biology and Endocrinology 2004, 2:52 http://www.rbej.com/content/2/1/52
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and that higher level expression of these factors is
dominant in the stable hybrids. Interestingly, the levels of
IRF-1, IRF-2 and STAT-1 expression in the trophoblast/
fibroblast hybrids were similar to the parental fibroblasts
[44,45], which is consistent with, but does not prove, the
possibility that the failure of trophoblast cells to express
CIITA may in part be due to sub-threshold levels of these
DNA binding proteins. Alternatively, trophoblast cells
may have deficiencies in factor(s) such as HAT(s), that
plays a crucial role in controlling the chromatin structure
at the CIITA type IV promoter, since histones are not
acetylated at the CIITA promoter in Jar or JEG-3 cells [40]
and TSA partially alleviates silencing of IFN-γ-inducible
CIITA expression in mouse trophoblast cells [15]. Lastly,
trophoblast cells may contain a factor(s) that represses
CIITA transcription, perhaps by recruiting histone
deacetylases. In this scenario, expression of this putative
repressor factor would be extinguished in the hybrids. It
Schematic of a general model for the silencing of CIITA transcription in trophoblasts Figure 2
Schematic of a general model for the silencing of CIITA transcription in trophoblasts. The CIITA PIV is associated 
with HDACs (red circles) in CIITA-inducible cells and trophoblasts in the absence of IFN-γ, which helps to maintain a closed 
chromatin conformation (represented as blackened bars). IRF-2 may or may not be bound constitutively to the CIITA PIV in 
CIITA-inducible cells. Following exposure of the cells to IFN-γ, STAT-1 (blue rectangle) is phosphorylated (represented by the 
red dot), and subsequently dimerizes, translocates to the nucleus, and induces synthesis of IRF-1 (yellow ovals), but the levels 
of these factors are higher in CIITA-inducible cells relative to trophoblasts. STAT-1 and IRF-1 bind to their respective elements 
at the PIV in CIITA-inducible cells, and recruit HATs (light green circles) to the promoter. This leads to changes in the chroma-
tin to an open conformation (light gray bars) and initiation of transcription. In contrast, this sequence of events does not occur 
in trophoblasts, and the chromatin remains in a closed conformation.
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remains to be determined whether this is the case for the
trophoblast-specific utRNA described by Peyman [47] and
Geirsson et al. [48,49].
Conclusions
Silencing of CIITA transcription in trophoblast cells is
likely to be crucial for successful maintenance of the fetus,
and recent studies suggest that the precise mechanism of
silencing may be novel. Therefore, we propose the follow-
ing general model to describe the mechanism by which
CIITA is silenced in trophoblast (Figure 2). In the absence
of IFN-γ, the CIITA PIV is associated with histone deacety-
lases (HDACs) and is therefore in a closed chromatin con-
formation in CIITA-inducible cells (fibroblasts, epithelial
and endothelial cells), and trophoblast cells. The precise
chromatin conformation of PIV may differ between tro-
phoblast and the CIITA-inducible cell types because IRF-
2, which is constitutively expressed at higher levels in
CIITA-inducible cells compared to trophoblast cells [45],
may be bound to the IRE in CIITA-inducible cells prior to
IFN-γ treatment. Following exposure to IFN-γ, STAT-1 is
activated, and IRF-1 synthesized in all of the cell types, but
the levels of these factors are reduced in trophoblast cells
relative to CIITA-inducible cells. These factors successfully
bind to their respective elements at the CIITA PIV in
fibroblasts, epithelial and endothelial cells, but fail to do
so stably in trophoblast. Histone acetyltransferases
(HATs) are subsequently recruited to the CIITA PIV by
STAT-1 and the IRFs in CIITA-inducible cells, and HDACs
are displaced, which results in further "opening" of the
chromatin, and induction of CIITA transcription. In con-
trast, HDACs remain associated with PIV in trophoblast
cells because the HATs are not recruited, and the CIITA
PIV chromatin conformation remains closed.
The elucidation of the silencing of CIITA in trophoblast
cells will shed light on one of the novel mechanisms by
which the fetus may evade rejection by the maternal
immune system during pregnancy. These studies may also
have important implications for tumor immunity, for
they will enable us to determine whether tumor cells that
fail to express CIITA (and hence MHC class II) are usurp-
ing normal cellular mechanisms of gene regulation to
evade host immune responses. Lastly, these studies may
have an impact on autoimmunity and transplantation, for
aberrant expression of MHC class II antigens is associated
with certain autoimmune disorders, and class II antigens
are one of the targets in transplant rejection.
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